Revenues for 2024 at 66.1930 trillion won, operating profit at 23.4673 trillion won, net profit at 19.7969 trillion won Revenues for Q4 at 19.7670 trillion won, operating profit at 8.0828 trillion won, net profit at 8.0065 trillion won Achieving best-ever quarterly and yearly performance…

Several leading classes of therapies are exploring diverse mechanisms of action to treat CHF, including SGLT2 inhibitors, cardiac myosin activators, myeloperoxidase inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, cell therapies, and more. This growing focus is…

The high and growing incidence of tuberculosis (TB) cases globally, especially in high-burden countries, is a major driver for both the treatment drugs and diagnostics markets. TB remains a significant public health challenge, with millions of new cases reported each year, particularly in…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.